Megakaryocytes, which differentiate from hematopoietic stem cells, represent only 0.4% of the total bone marrow cells 3) and produce PLTs through multiple stages. 4) Although thrombopoietin (TPO) was identified as the only potential differentiation factor for megakaryocytopoiesis, 5, 6) it somewhat inhibits PLT production from mature megakaryocyte. 7) Therefore, it has insufficient activity in cancer-chemotherapy-induced thrombocytopenia (CIT).
For the development or design of medications to achieve the recovery of PLT counts, we have focused on the production-mechanisms of PLT from megakaryocytes. Many studies have tried to identify molecules associated with PLT production, yet few, if any, have been defined. In transcription factor p45 subunit of nuclear factor erythroid 2 (NF-E2 p45) deficient mice, severe thrombocytopenia was observed. 8) However, deficiencies of Thromboxane synthase (TXS) and b1-tubulin, known as the target molecules of NF-E2, [9] [10] [11] did not result in complete attenuation of PLT production. 12) Hence, it is accepted that those molecules are strongly associated with PLT function, but are not critical for PLT production.
Gene expression profiling using oligonucleotide microarrays has recently become established as a useful tool for seeking candidate target molecules. This technique could be applicable to identify the molecules that are closely related to PLT production. However, due the low abundance of primary megakaryocytes, they are not preferred as a source for a comprehensive gene expression analysis using a microarray. MEG-01 cells, a human megakaryocytic leukemia cell line, 13 ) is a popular cell line that has been used in megakaryocyte differentiation studies, in gene function validation studies in megakaryocytopoiesis, in studies of PLT-like particle production, ploidy, and for the study of in vivo tumorigenesis. 14) It has been confirmed that MEG-01 cells are committed to the megakaryocytic lineage and can produce PLT-like particles. 15) In addition, it was reported that treatment with phorbol myristate acetate (PMA) enhanced the differentiation of MEG-01 cells, 16) leading to the possibility that PMA-treatment could enhance the production of PLT-like particles from the MEG-01 cells. Accordingly, MEG-01 cells may be a good source for identifying the critical genes for PLT production by means of a RT-PCR.
In this study, we treated MEG-01 cells with PMA to enhance the production of PLTs from the cells. We then performed a comprehensive gene expression analysis in order to define genes strongly related to PLT production. The results indicated that MEG-01 cells might be a suitable model to study the process of PLT production in thrombopoiesis and that the gene-expression analysis also may be a powerful tool to identify genes relating to PLT production.
MATERIALS AND METHODS

Materials
Recombinant human thrombopoietin (rhTPO) was purchased from Peprotech (NJ, U.S.A.). Bovine serum albumin (BSA), EDTA, and phorbol myristate acetate (PMA) 4 cells) were seeded in a well of a 48-well plate and incubated with PMA (10 nM) or rhTPO (10 ng/ml) for 1 to 5 d at 37°C. After incubation, the number of PLTlike particles derived from MEG-01 cells was counted using an EPICS XL-MCL flow cytometer (Beckman Coulter, CA, U.S.A.). After treatment with phosphate-buffered saline (PBS) containing 0.5 M EDTA, the cells were collected by centrifugation (1710ϫg) for 10 min at 4°C, and stained with FITC-conjugated anti-human CD41 (gpIIb) monoclonal antibody (mAb) (TP-80, Nichirei, Tokyo, Japan). Twenty thousand units of Flow Count (Beckman Coulter) were added to each sample as an internal control. The derived PLT-like particles per 1000 units of Flow Count were enumerated as CD41 ϩ events with the same forward/side scatter properties as human peripheral blood PLTs.
RNA Purification and GeneChip Analysis MEG-01 and U937 cells (1ϫ10 6 cells) were seeded in a 25 cm 2 -culture flask and incubated with PMA (10 nM) for 8 or 24 h at 37°C. After incubation, the cells were collected by centrifugation (1710ϫg) for 10 min at 4°C, and total RNA was isolated using an RNeasy mini kit (QIAGEN, CA, U.S.A.) according to the manufacturer's protocol. The concentration of isolated total RNA in each sample was determined by absorption at 260 nm using an Ultrospec3000 photo spectrometer (Amersham Pharmacia, Uppsala, Sweden). Biotin-labeled target cRNA was prepared from 10 mg of total RNA from each sample and hybridized to Human Genome U133A and B GeneChips (Affymetrix, CA, U.S.A.). The hybridized chips were washed, stained with SA-PE solution, and then scanned at a wavelength of 570 nm using an Affymetrix HP GeneArray Scanner (Affymetrix). Data were analyzed with GeneSpring 6.0 (Silicongenetics, CA, U.S.A.). At first, values below 0.01 were set to 0.01. Data were normalized in two ways: per chip normalization and per gene normalization. For per chip normalization, all expression data on a chip were normalized to the 50th percentile of all values on that chip. For per gene normalization, all samples were normalized against the measurement of the control sample, untreated MEG-01 and U937 cells (measurements for each gene in those samples were divided by the measurement of the control sample). The analysis conditions are shown in below:
Up-Regulated Genes: At 0, 8 and 24 h, the detection call was "P" (Present). Both of the expression at 8 h and 24 h were more than twice that at 0 h. The expression at 24 h was higher than that at 8 h.
Down-Regulated Genes: At 0 h, the detection call was "P". Both of the expressions at 8 h and 24 h were below half that at 0 h. The expression at 24 h was lower than that at 8 h.
RT-PCR MEG-01 cells were seeded at a density of 5ϫ10 4 cells/ml and treated with PMA (10 nM) for 1, 2, 4, 8, 24, 48 or 72 h at 37°C. After treatment, the cells were collected by centrifugation (1710ϫg, 10 min, 4°C), and total RNA was isolated using an RNeasy mini kit according to the manufacturer's protocol. Total RNA extracted from each cell pellet was reverse transcribed into cDNA using M-MLV Reverse Transcriptase (Invitrogen, CA, U.S.A.) and random primers (Takara, Shiga, Japan) in a 20 ml mixture and diluted to 100 ml with distilled water. Subsequent PCR amplification (50 ml) was performed with 5 ml of cDNA solution using TaKaRa Ex Taq in the presence of specific primer pairs. Each cycle of PCR consisted of 30 s at 95°C, 30 s at 58°C, and 1 min at 72°C. The following oligonucleotides were used as primers: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense primer, 5Ј-TGAAGGTCGGAG-TCAACGGATTTGGT-3Ј, antisense primer, 5Ј-CATGTG-GGCCATGAGGTCCACCAC-3Ј, TXS (thromboxane synthase) sense primer, 5Ј-CCTCTGTGTGGGTACTATCTTG-G-3Ј, antisense primer, 5Ј-TGGGACCATTATGGATGGAA-ATG-3Ј, b1-tubulin, sense primer, 5Ј-GCATTCGATCTAG-CAAATTAGGAGCTC-3Ј, antisense primer, 5Ј-CTCAATC-AGCTGGTGGATAGACAGAACC-3Ј, CD62P (P-selectin), sense primer, 5Ј-GAACTTGAGCTCCCTCAACACGTGCT-CATG-3Ј, antisense primer, 5Ј-CACATTATTGGGCCCCT-CCAGCTTAAAGCC-3Ј, CD41 (gpIIb), sense primer, 5Ј-AGTGCCCCTCGCTGCTCTTTGACC-3Ј, antisense primer, 5Ј-AGTTTTCGGTCTGCCCGGCTCTC-3Ј; CD61 (gpIIIa), sense primer, 5Ј-AGATGCGAAAGCTCACCA-3Ј, antisense primer, 5Ј-TGAGCTCACTATAGTTCTG-3Ј, mafK, sense primer, 5Ј-ATGACGACTAATCCCAAACCG-3Ј, antisense primer, 5Ј-CTAGGATGCAGCCGAGAAGGG-3Ј, PAI-I, sense primer, 5Ј-GAACAAGGATGAGATCAGCACC-3Ј, antisense primer, 5Ј-ACTATGACAGCTGTGGATGAGG-3Ј. CD42b (gpIba), sense primer, 5Ј-AAGCTGGAGAAGCT-CAGTCTGG-3Ј, antisense primer, 5Ј-CTCCTTAGTGGAT-TCTTGTGTTGG-3Ј
Statistics Two-way analysis of variance and Dunnett's multiple comparison test was used in order to analyze the differences between the control group and the PMA treated, or TPO-treated group. The level of significance was set at pϽ0.05.
RESULTS
Production of PLT-like Particles from MEG-01 Cells by PMA Treatment Following a 3 d-incubation of MEG-01
cells with or without PMA or rhTPO, the number of PLT-like particles (cells that could be stained with fluorescence-labeled anti-human CD41 Ab) in the medium was determined by flow cytometry. For PLT-like particle gating, a region 1 (R1) was designated by the loading of human peripheral PLTs following staining with fluorescence-labeled antihuman CD41 Ab (data not shown). The designated region shown in Fig. 1A was loaded with unstained control. In the absence of PMA, slight staining of PLT-like particles was detected in the designated region (Fig. 1B) . The number of PLT-like particles was increased by treatment with PMA (Fig. 1C) , while the number was not increased by treatment with rhTPO (Fig. 1D) .
The effect of time of incubation with PMA on the production of PLT-like particles from MEG-01 cells was investigated. The number of PLT-like particles in the incubation media increased with increasing time of incubation in the presence of PMA (Fig 2) . The number of PLT-like particles was 1.5-fold higher than those in the presence of rTPO and in the absence of PMA (control). It appears that MEG-01 cells can produce PLT-like particles without PMA treatment, which is consistent with previously reported observations. 17) The PMA treatment obviously accelerated the rate of PLTlike particle production from MEG-01 cells. It has been reported that rhTPO promotes the differentiation of megakaryocytes, but does not enhance PLT production from megakaryocytes 7) and our results confirm this observation. These results strongly suggest that a PMA-treated MEG-01 cell line is a good source for analyzing genes related to PLT production.
Comprehensive Gene Expression Analysis by Means of Microarray
The comprehensive gene expression analysis was performed at 8 and 24 h of incubation with PMA by means of microarrays, Human Genome U133A and B GeneChips, to detect genes that were affected during PLTlike particle production in MEG-01 cells. To exclude non megakaryocyte-related genes, U937 cells, a human monocytic cell line, were employed as a control cell line. The conditions for selecting up-or down-regulated genes are shown in the Materials and Methods. As shown in a Venn diagram (Fig. 3) , genes that were up-or down-regulated genes only in MEG-01 cells were141 and 164 genes, respectively. The differentially expressed genes were classified into different categories on the basis of their functions ( Table 1 ). The results indicated that the expressions of genes relating to cell proliferation and differentiation were affected by PMA treatment. However, genes relating to megakaryocyte differentiation or PLT-function (such as NF-E2, b1-tubulin, gpIIb (CD41), gpIba (CD42b), gpIIIa (CD61), gpIX, mafK, CD62P and TXS (18, 19) did not appear to be differentially expressed.
Gene Expression Analysis by Means of RT-PCR
Gene expression analysis in MEG-01 cells relating to PLT production was also performed at 1, 2, 4, 8, 24, 48 and 72 h of incubation with PMA by means of RT-PCR (Fig. 4) . The enhancement of expression of b1-tubulin, CD62P and TXS was detected after 24 h-incubation with PMA. The expression of megakaryocyte differentiation markers, gpIba (CD42b) and gpIIIa (CD61), also increased after 24 h-incubation with 356 Vol. 32, No. 3 TIFA   TNIP2   TTC30A   UBAC2   WDR89   ZDHHC8 PMA.
DISCUSSION
Megakaryocytes, among the rarest of hematopoietic cells, serve the essential function of producing PLTs.
3) Mechanisms of thrombopoiesis are of considerable interest in hematology and cell biology. PLT production is especially important because it is the main method for quick recovery in severe thrombocytopenia. One of the barriers to the clarification of the mechanism of PLT production has been the difficulty in obtaining sufficient numbers of megakaryocytes, because mature megakaryocytes are only 0.4% of the total bone marrow cells. 3) In this study, we employed MEG-01 cells, a human megakaryocytic leukemia cell line, 13) as an alternative source of megakaryocytes. The cell line has been shown to produce PLT-like particles. 15, 17) It has also been reported that PMA treatment enhances the differentiation of MEG-01 cells. 20) However, there has been no report indicating that PMA-treatment accelerates the production of PLTlike particles from MEG-01 cells. Therefore, we attempted to use PMA to enhance PLT production from MEG-01 cells. As shown in Figs. 1 and 2 , we confirmed the production of PLTlike particles from MEG-01, and showed that PMA accelerated the production. Thus the PMA-treated MEG-01 cells are a good system for studying human PLT production.
We then performed a comprehensive gene expression analysis on PMA-treated MEG-01 cells using microarrays. We hoped that this genetic study would provide insights into the molecular and transcriptional regulation of thrombopoiesis. We detected many genes that were up-or down-regulated specifically in the PMA-treated MEG-01 cells (Fig. 3 , Table 1 ). Most of those are similar to those reported by Raslova et al. for human megakaryocytes derived from CD34 ϩ cells. 21) Unfortunately, changes in PLT-related gene expressions were not detected under these experimental conditions. Initially, we expected to identify genes associated with the early phase of PLT production. Figure 4 changes in the expressions of genes (b1-tubulin, CD62P, TXS etc.) associated with PLT function 22) following 8 h or 24 h-incubation with PMA. This suggests that the selected time points (8, 24 h) might be too early to detect the change in mRNA levels relating to PLT-production, even though the cells were stimulated by PMA treatment. Further studies are required to optimize the experimental conditions for microarray analysis.
RT-PCR study indicated enhanced gene expression of PLTrelated markers such as b1-tubulin, CD62P and TXS 18) and megakaryocyte differentiation markers such as gpIba (CD42b) and gpIIIa (CD61), starting at least 24 h after incubation with PMA (Fig. 4) . In addition, the study showed that those expression levels tended to reach a maximum around 48 h (Fig. 4) . b1-tubulin is considered to be important for the late phase of megakaryocyte differentiation and the early phase of PLT production. 10) Thus the result of RT-PCR study suggests that the gene expression levels relating to PLT-production increase following 48 h-incubation with PMA. In addition, the pattern of gene expressions (Fig. 4) is consistent to the pattern of PLT-production described in Fig. 2 . This might mean that the PMA-treated MEG-01 cells are an alternative model system for studying the process of PLT production from megakaryocytes.
One function of bone marrow megakaryocytes (Mks) is the controlled release of PLTs into the circulation (thrombopoiesis). Over the past half decade, the molecular mechanism that contributes to PLT production has begun to be elucidated. Several fundamental questions and hypotheses on the molecular mechanism of Mks commitment, the precise role of some transcription factors and the endomitotic process still need to be addressed. Determination of the detailed transition from Mks to PLTs and, more precisely, the characterization of the molecules related to PLT release will be also extremely important. Knowledge of genes relating to PLT production will provide the basis for novel therapeutic approaches for modulation of PLT number and function. Recently, we established a gene-transfer system for MEG-01 cells. 23) These powerful tools, including the gene delivery system and this comprehensive gene expression analysis of PMA-treated MEG-01 cells, will help future studies of, and search for, novel molecules related to PLT-production.
